234 related articles for article (PubMed ID: 31874704)
1. RF-Cemiplimab: First Drug Approved for the Treatment of Metastatic or Unresectable Cutaneous Squamous Cell Carcinoma.
Morgado-Carrasco D; Bosch-Amate X; Fustà-Novell X; Giavedoni P
Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):161-163. PubMed ID: 31874704
[No Abstract] [Full Text] [Related]
2. Cemiplimab: First Global Approval.
Markham A; Duggan S
Drugs; 2018 Nov; 78(17):1841-1846. PubMed ID: 30456447
[TBL] [Abstract][Full Text] [Related]
3. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
Migden MR; Khushalani NI; Chang ALS; Lewis KD; Schmults CD; Hernandez-Aya L; Meier F; Schadendorf D; Guminski A; Hauschild A; Wong DJ; Daniels GA; Berking C; Jankovic V; Stankevich E; Booth J; Li S; Weinreich DM; Yancopoulos GD; Lowy I; Fury MG; Rischin D
Lancet Oncol; 2020 Feb; 21(2):294-305. PubMed ID: 31952975
[TBL] [Abstract][Full Text] [Related]
4. First Drug Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma.
Aschenbrenner DS
Am J Nurs; 2019 Jan; 119(1):27. PubMed ID: 30589700
[No Abstract] [Full Text] [Related]
5. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.
Lee A; Duggan S; Deeks ED
Drugs; 2020 Jun; 80(8):813-819. PubMed ID: 32306208
[TBL] [Abstract][Full Text] [Related]
6. Cemiplimab removed from reimbursable drugs in France.
Pham F; Reynaud B; Favier B; Darnis S; Amini-Adle M
Eur J Cancer; 2021 May; 149():11-13. PubMed ID: 33812142
[No Abstract] [Full Text] [Related]
7. Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation.
Ali SA; Arman HE; Patel AA; Birhiray RE
JCO Oncol Pract; 2020 Mar; 16(3):137-138. PubMed ID: 31770056
[No Abstract] [Full Text] [Related]
8. Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma.
Hanania HL; Lewis DJ
Expert Rev Anticancer Ther; 2022 Feb; 22(2):237-238. PubMed ID: 34918605
[No Abstract] [Full Text] [Related]
9. Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Konidaris G; Paul E; Kuznik A; Keeping S; Chen CI; Sasane M; Xu Y; Atsou K; Ayers D; Ruiz ES; Khushalani NI; Cope S
Value Health; 2021 Mar; 24(3):377-387. PubMed ID: 33641772
[TBL] [Abstract][Full Text] [Related]
10. Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma.
Vaccaro M; Bertino L; Santarpia M; Altavilla G; Cannavò SP
Dermatol Ther; 2020 Nov; 33(6):e14417. PubMed ID: 33068047
[No Abstract] [Full Text] [Related]
11. Novel treatment of locally advanced cutaneous squamous cell carcinoma with cemiplimab: a case report.
Nelson R; Luu L; Silberstein P; Velagapudi M; Huerter C
Int J Dermatol; 2021 Feb; 60(2):233-235. PubMed ID: 32955136
[No Abstract] [Full Text] [Related]
12. Cemiplimab in advanced cutaneous squamous cell carcinoma.
Naik PP
Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
[TBL] [Abstract][Full Text] [Related]
13. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG
N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979
[TBL] [Abstract][Full Text] [Related]
14. Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus.
Gambichler T; Hessam S; Lüttringhaus T; Boms S
Clin Exp Dermatol; 2022 Mar; 47(3):608-609. PubMed ID: 34767651
[TBL] [Abstract][Full Text] [Related]
15. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E
Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149
[TBL] [Abstract][Full Text] [Related]
16. Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab.
Venkatesh S; Al-Haseni A; Sahni D
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31377718
[TBL] [Abstract][Full Text] [Related]
17. Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab.
Di Prima A; Botticelli A; Scalzulli E; Colafigli G; Pepe S; Lisi C; Marchetti P; Martelli M; Foà R; Breccia M
Ann Hematol; 2021 Aug; 100(8):2117-2119. PubMed ID: 32856142
[No Abstract] [Full Text] [Related]
18. Immunotherapy in Squamous Cell Skin Carcinoma: A Game Changer?
Ravulapati S; Leung C; Poddar N; Tu Y
Am J Med; 2017 May; 130(5):e207-e208. PubMed ID: 28249663
[No Abstract] [Full Text] [Related]
19. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.
Ahmed SR; Petersen E; Patel R; Migden MR
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530
[No Abstract] [Full Text] [Related]
20. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
Actas Dermosifiliogr; 2022 Jun; 113(6):T610-T615. PubMed ID: 35525283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
